<?xml version='1.0'?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:georss="http://www.georss.org/georss" xmlns:atom="http://www.w3.org/2005/Atom" >
<channel>
	<title><![CDATA[BOL: Tivicay® (dolutegravir) 50-mg tablets for HIV-1]]></title>
	<link>https://bioinformaticsonline.com/news/view/2488/tivicay%C2%AE-dolutegravir-50-mg-tablets-for-hiv-1?</link>
	<atom:link href="https://bioinformaticsonline.com/news/view/2488/tivicay%C2%AE-dolutegravir-50-mg-tablets-for-hiv-1?" rel="self" type="application/rss+xml" />
	<description><![CDATA[]]></description>
	
	<item>
	<guid isPermaLink="true">https://bioinformaticsonline.com/news/view/2488/tivicay%C2%AE-dolutegravir-50-mg-tablets-for-hiv-1</guid>
	<pubDate>Fri, 16 Aug 2013 09:00:15 -0500</pubDate>
	<link>https://bioinformaticsonline.com/news/view/2488/tivicay%C2%AE-dolutegravir-50-mg-tablets-for-hiv-1</link>
	<title><![CDATA[Tivicay® (dolutegravir) 50-mg tablets for HIV-1]]></title>
	<description><![CDATA[<p>FDA has approved Viiv Healthcare&rsquo;s integrase inhibitor Tivicay&reg; (dolutegravir) 50-mg tablets, for use with other antiretroviral agents in treating HIV-1 infection. ViiV Healthcare is an HIV therapeutics company established in 2009 by GlaxoSmithKline and Pfizer.</p><p>Tivicay is indicated for infected adults, both treatment-naive and treatment-experienced, including those treated with other integrase strand transfer inhibitors; as well as for children aged 12 years and older weighing at least 40 kg (approx. 88 lbs). The drug - which was used without a pharmacokinetic boosting agent - interferes with one of the enzymes necessary for HIV to multiply, and can be taken with or without food and at any time of day.</p><p>http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm364869.htm</p>]]></description>
	<dc:creator>Neel</dc:creator>
</item>

</channel>
</rss>